The nuclear medicine market is poised for remarkable growth, with an anticipated Compound Annual Growth Rate (CAGR) of 4.30%. The industry is projected to surpass to US$ 6.49 billion mark in terms of value, reflecting increasing demand for advanced diagnostic and therapeutic procedures. Factors driving this growth include technological advancements, rising prevalence of chronic diseases, and growing awareness about the benefits of nuclear medicine in personalized treatments. The market's upward trajectory signifies promising opportunities for key players and stakeholders in the nuclear medicine sector.
The report "Nuclear Medicine Market, By Diagnostics (Single Photon Emission, Computed Tomography (SPECT), and Positron Emission Tomography (PET)), By Therapeutics (Alpha Emitters, Beta Emitters, and Brachytherapy), By Applications (Cardiology, Neurology, Oncology, and Other Applications), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3827
Key Highlights:
• In 2021, Penn Medicine’s clinical, operational, and research and clinical capabilities, the health system is launching the Center for Applied Health Informatics to better facilitate and coordinate health data projects across the health system and grow its leadership in health informatics globally.
• In 2021, Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation).
Analyst view:
From an analyst's perspective, the nuclear medicine market presents an exciting and optimistic outlook. The projected 4.30% CAGR indicates strong potential for sustained growth over the forecast period. Technological innovations and advancements in imaging and therapy techniques are expected to drive the market's expansion, enabling more accurate diagnoses and effective treatments for various medical conditions. Additionally, the rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, is likely to fuel the demand for nuclear medicine procedures. As awareness regarding the benefits of personalized treatments using nuclear medicine continues to grow, the market is poised to exceed be US$ 6.49 billion in value, offering lucrative opportunities for investors and industry players. However, it is essential to closely monitor regulatory developments and reimbursement policies to ensure the market's continued progress and success. Overall, the nuclear medicine market appears to be a promising sector with considerable potential for both short-term and long-term growth.
Competitive Landscape:
The key players operating the global nuclear medicine market involves Eckert & Ziegler Group, Mallinckrodt Pharmaceuticals, GE Healthcare; Jubilant Life Sciences; Bracco Imaging S.p.A, Nordion, Inc., The Institute of Radioelements, Australian Nuclear Science & Technology Organization (ANSTO), NTP Radioisotopes SOC Ltd., and Eczacibasi-Monroe.The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
RoW: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com